GLP-1 Medications for Weight Management: What the Evidence Says

The GLP-1 class did something obesity medicine had been trying and failing to do for forty years: it produced weight loss large enough to change the clinical conversation. It also produced a marketing industry that is considerably less careful than the science it borrows from.

What follows is what the evidence supports, what it does not, and the specific things worth understanding before you start. Some of it is unflattering to the category. That is the point of writing it.

What these drugs actually do

When food reaches your intestine, cells in the gut wall release hormones called incretins. Two of them matter here. GLP-1, glucagon-like peptide-1, comes from cells in the lower small intestine and colon. GIP, glucose-dependent insulinotropic polypeptide, comes from cells further up.

Natural GLP-1 does several things at once. It prompts the pancreas to release insulin, but only when blood glucose is elevated, which is why the class does not cause hypoglycaemia on its own the way older diabetes drugs do. It suppresses glucagon, the hormone that tells the liver to release stored glucose. It slows the rate at which the stomach empties, so a meal stays with you longer. And it signals to appetite-regulating regions of the hypothalamus and brainstem, which is where most of the weight effect comes from.

The catch with the natural hormone is that it survives in the bloodstream for a couple of minutes before an enzyme dismantles it. The pharmaceutical achievement was building molecules that do the same job and last a week. That is the whole story of semaglutide and tirzepatide in one sentence.

The subjective experience of that is what patients describe as food going quiet. Not willpower arriving, but the background hum of thinking about food dropping out. The phrase people use is "food noise," and it did not come from researchers; it came from patients, independently, in nearly identical words. That consistency is itself informative, and we have written about what the phenomenon suggests about appetite regulation.

Semaglutide and tirzepatide

Semaglutide is a GLP-1 receptor agonist, given as a weekly injection. It is marketed under different brand names for different indications: one for type 2 diabetes, one for chronic weight management. There is also an oral formulation. The molecule is the same; the approved indication and the dose range differ.

Tirzepatide is a dual agonist. It activates the GLP-1 receptor and the GIP receptor. GIP's role in energy balance is still being worked out, and the mechanistic explanation for why adding it helps is not fully settled. What is clear from the trials is that it does. In the direct head-to-head comparison against semaglutide in people with obesity, tirzepatide produced greater average weight reduction.

Averages are not individuals. Response varies widely between people on both drugs, tolerability differs, and cost and supply are real inputs into the decision rather than footnotes. The full comparison of the two goes through the practical factors that usually decide it.

What the major trials broadly showed

The semaglutide weight-management programme, published as the STEP trials, and the tirzepatide programme, published as SURMOUNT, both tested the drugs against placebo alongside lifestyle intervention. Both produced average weight reductions substantially beyond anything previous weight-loss pharmacotherapy had achieved, and substantially beyond placebo. Tirzepatide's figures ran higher than semaglutide's, and the head-to-head study later confirmed that ordering directly.

Separately, and arguably more importantly, a large cardiovascular outcomes trial found that semaglutide reduced major adverse cardiovascular events in people with overweight or obesity and established cardiovascular disease who did not have diabetes. That result moved these drugs out of the cosmetic conversation entirely. Tirzepatide has also been approved for obstructive sleep apnoea in adults with obesity on the strength of its own trial data.

What the trials do not show is who will respond well. There is no reliable predictor at the individual level, and a substantial minority of participants in every trial lost far less than the average.

Titration, and why it is deliberately slow

Treatment starts at a dose too low to do much and steps up over months, typically at four-week intervals, until you reach either the target dose or the highest dose you tolerate.

The reason is gastrointestinal. Nausea, vomiting, diarrhoea, constipation and reflux are the common effects, they are dose-related, and they are far worse if you jump. Slow escalation lets the gut adapt. Most people find the first days after each increase are the difficult ones and that it settles.

A provider who offers to start you high, or to accelerate the schedule because you want faster results, is not being responsive. They are trading your tolerability for a number on a scale. The correct dose is the lowest one that is working, not the highest one on the label.

Not everyone reaches the top dose, and not everyone needs to. Some people do well at a middle dose indefinitely.

Side effects: common, and serious

The common ones are the gut effects above, plus fatigue and headache early on. They are unpleasant, usually manageable, and usually improve. Eating smaller portions, slowing down, reducing fat and fibre volume in the first weeks and staying well hydrated all help more than people expect. We go through practical management in a dedicated article on GLP-1 side effects.

The serious ones are a different list and deserve to be named plainly.

Pancreatitis. Severe, persistent abdominal pain, often radiating to the back, often with vomiting, is a stop-taking-it-and-be-seen symptom. Do not wait it out.

Gallbladder disease. Gallstones and gallbladder inflammation occur more often on these drugs, partly a consequence of rapid weight loss in general.

Severe gastrointestinal obstruction and gastroparesis. Rare, but reported. Persistent vomiting, inability to keep fluids down and abdominal distension all warrant urgent assessment.

Dehydration and kidney injury. Almost always secondary to vomiting or diarrhoea that went on too long. This is one of the most common reasons people on these drugs end up in hospital, and it is largely preventable.

Diabetic retinopathy. In people with existing retinopathy, rapid glucose improvement can worsen it. That is a known phenomenon with any rapid glycaemic correction and is a reason for ophthalmic monitoring, not a reason to avoid treatment.

Hypoglycaemia in combination. On its own the class rarely causes low blood sugar. Combined with insulin or a sulfonylurea it certainly can, and those doses usually need adjusting.

An eye condition involving sudden vision loss has been reported in association with semaglutide and reviewed by regulators, who have characterised it as very rare. It is an active area of pharmacovigilance rather than a settled finding, and it belongs in the "watch this space" column rather than either the dismissed or established one.

Who should not take these drugs

The absolute contraindications are narrow and firm.

A personal or family history of medullary thyroid carcinoma, or of multiple endocrine neoplasia syndrome type 2, rules these drugs out. This comes from thyroid C-cell tumours seen in rodent studies, and whether the rodent finding translates to humans is genuinely unresolved. The regulatory response has been to exclude anyone in whom that risk would be unacceptable, and that position has not moved.

Pregnancy is a contraindication, and because these drugs persist for weeks, discontinuation needs to happen well before a planned conception rather than on discovering a pregnancy. Anyone who might become pregnant should have that conversation before starting, not after. Worth noting also that weight loss and slowed gastric emptying can affect oral contraceptive absorption for some people.

Beyond the absolutes there are cautions: a history of pancreatitis, existing gastroparesis or severe reflux, active gallbladder disease, type 1 diabetes, significant kidney impairment, and a history of an eating disorder, which is a serious and frequently ignored consideration in a drug whose mechanism is appetite suppression. Our article on who should not take a GLP-1 covers each of these.

If a provider prescribes one of these without asking about your thyroid history, your family history, your pancreas, your pregnancy plans and your full medication list, they are not conducting a medical evaluation. They are processing an order.

Compounded versus branded

This is the part of the market that generates the most confusion, and it is worth being precise.

Branded semaglutide and tirzepatide products are FDA-approved. They went through the approval process, they are made under the manufacturer's controls, and the label reflects reviewed data.

Compounded semaglutide and compounded tirzepatide are not FDA-approved. Not "approved under a different route," not "approved as a generic." There are no generic versions of these molecules, because the patents have not expired. A compounded preparation is made by a pharmacy, and the FDA does not review it for safety, effectiveness or manufacturing quality before it is dispensed.

Compounding of copies was widespread during the periods when FDA listed these drugs as being in shortage, because shortage status creates a legal pathway that would not otherwise exist. The agency subsequently declared those shortages resolved, which closed that pathway and set deadlines for pharmacies to stop. That has been litigated and the details have shifted more than once, so the current position is something to verify against FDA's own shortage database rather than against a clinic's marketing page.

Two specific hazards are worth naming. First, some products have been sold containing salt forms of the molecule, such as semaglutide sodium or semaglutide acetate. FDA has stated these are not the same active ingredient as the approved drug, and their safety and effectiveness have not been established. Second, dosing errors. Compounded product often arrives as a vial and a syringe, with instructions in units or millilitres rather than a pen that clicks to a dose, and there have been serious overdoses from people drawing up ten times the intended amount. Those are not exotic edge cases; they are reported adverse events.

None of this means every compounding pharmacy is dangerous. It means the safety guarantees you assume are attached to a prescription medicine are not attached in the same way here, and you should know that going in. We set out the full picture, including the questions to ask, in compounded GLP-1s: what to understand before you buy.

Muscle

Weight lost is not only fat. A meaningful share of the mass lost during rapid weight reduction is lean tissue, and that is true of any rapid weight loss, not something peculiar to this drug class. But because these drugs produce so much loss so quickly, the absolute quantity of lean mass involved is larger than with older approaches.

Lean mass matters. It is a large part of your resting energy expenditure, it is the basis of physical function and it becomes progressively harder to rebuild with age. Losing it makes maintenance harder later.

The two things with the best evidence behind them are unglamorous: adequate protein intake, which is harder than it sounds when your appetite has been switched off, and resistance training. Not cardio in addition to, but resistance training specifically. This deserves more attention than it usually gets, and we give it that in losing muscle on a GLP-1.

Stopping

The trials that followed people after withdrawal are the ones that reframe the whole category. When treatment stops, appetite returns and weight regain follows. Most of the lost weight comes back over the subsequent period, and the cardiometabolic improvements largely regress with it.

This is not a failure of discipline and it is not a criticism of the drug. It is what treating a chronic condition looks like when you withdraw the treatment. Nobody expects blood pressure to stay down after stopping an antihypertensive. Obesity has a physiology that defends body weight, and the drug works by counteracting that physiology, not by permanently altering it.

The practical implication is that you should decide at the start whether you are prepared for this to be long-term, because a twelve-week course is a poor use of the drug and of your money. What happens when you stop a GLP-1 goes into the follow-up data.

Where to go from here

These are serious medicines with a real evidence base, a real risk profile and a real need for follow-up. They are not a shortcut and they are not appropriate for everyone who wants to lose weight. A proper evaluation covers your full history, your other medications, your labs where indicated, and an honest conversation about what happens after year one.

Our medical weight management programme explains how that works, and you can book a consultation to discuss whether treatment fits your situation. Nobody can tell you in advance that you will be prescribed anything, or how much weight you would lose if you were. If a service tells you otherwise before speaking to you, that tells you what kind of service it is.